Semaglutide · 1 receptor
A 31-amino-acid GLP-1 analog with a fatty-acid chain that lets it bind albumin and last about a week. It targets the GLP-1 receptor. FDA approved in 2017.
Tirzepatide · 2 receptors
A 39-amino-acid peptide that activates both the GIP and GLP-1 receptors. FDA approved in 2022.
Retatrutide · 3 receptors
A 39-amino-acid peptide that activates GIP, GLP-1 and glucagon receptors. It is investigational and in Phase 3 trials.
About these models
Each chain uses its real published sequence, laid out on an idealized helix for clarity. Receptors are drawn as stylized class-B GPCRs: seven helices crossing the cell membrane, topped by a large outer domain.
